{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":22,"podcast":8,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04927780\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PREOPANC-3","nct_id":"NCT04927780","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=preopanc-3-nct04927780. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PREOPANC-3","arms":[{"description":"Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.","label":"Arm 1: Perioperative mFOLFIRINOX","type":"EXPERIMENTAL"},{"description":"Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.","label":"Arm 2: Adjuvant mFOLFIRINOX","type":"ACTIVE_COMPARATOR"}],"collaborators":["Dutch Pancreatic Cancer Group","Dutch Cancer Society"],"completion_date":{"date":"2029-07","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Adenocarcinoma"],"enrollment":{"count":378,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Leucovorin Calcium","type":"DRUG"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Irinotecan Hydrochloride","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Resection","type":"PROCEDURE"}],"last_update":"2026-05-15","lead_sponsor":"Erasmus Medical Center","official_title":"Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"Up to 5 years after randomization."}],"references":[{"citation":"van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, Busch OR, van Driel LMJW, van Eijck CHJ, Feshtali S, Ghorbani P, de Groot DJA, de Groot JWB, Haberkorn BCM, de Hingh IH, van der Holt B, Karsten TM, van der Kolk MB, Labori KJ, Liem MSL, Loosveld OJL, Molenaar IQ, Polee MB, van Santvoort HC, de Vos-Geelen J, Wumkes ML, van Tienhoven G, Homs MYV, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023 Aug 7;23(1):728. doi: 10.1186/s12885-023-11141-5.","pmid":"37550634","type":"BACKGROUND"}],"start_date":{"date":"2021-09-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT04927780"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/preopanc-3-nct04927780"}